Pancreatic Cancer Research

ResearcherBioplatinum Technologies, LlcActive in the last 2 years

Jose Gilberto Trevino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0265-8151; OpenAlex author ID A5052737510; NIH RePORTER profile ID 10416248. Sources: OpenAlex.

Their work

Papers
64 (first author 5, last author 17)
Trials
0
Grants
4
Labs led
2
Collaborators
160
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 6 papers · 2016: 3 papers · 2017: 5 papers · 2018: 5 papers · 2019: 3 papers · 2020: 5 papers · 2021: 7 papers · 2022: 11 papers · 2023: 6 papers, 1 grant · 2024: 3 papers, 1 grant · 2025: 5 papers · 2026: 2 papers, 2 grants

Papers 50 of 64

  1. Neoadjuvant Radiation is Causally Linked to Increased Operative Time and Perioperative Blood Transfusion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jss.2026.01.031↗
  2. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  3. A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Co-author DOI 10.1016/j.neo.2024.101070↗
  4. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  5. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-25-0237↗
  6. Complement pathway activation mediates pancreatic cancer-induced muscle wasting and pathological remodeling. Co-author DOI 10.1172/jci178806↗
  7. Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32110638↗
  8. Heterogeneity of weight loss and transcriptomic signatures in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jcsm.13390↗
  9. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0297325↗
  10. Unveiling the Promise: Navigating Clinical Trials 1978-2024 for PDAC. Co-author DOI 10.3390/cancers16213564↗
  11. The impact of race/ethnicity on pancreaticoduodenectomy outcomes for pancreatic cancer. Co-author DOI 10.1002/jso.27113↗
  12. Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity. Co-author DOI 10.1136/jitc-2023-007624↗
  13. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors. Co-author DOI 10.1158/2767-9764.crc-23-0222↗
  14. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. Co-author DOI 10.1186/s12885-023-10928-w↗
  15. Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients. Co-author DOI 10.1371/journal.pone.0281182↗
  16. Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers15184464↗
  17. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery. Co-author DOI 10.1002/cam4.4416↗
  18. A multi-omics approach identifies pancreatic cancer cell extracellular vesicles as mediators of the unfolded protein response in normal pancreatic epithelial c… Co-author DOI 10.1002/jev2.12232↗
  19. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2116764119↗
  20. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Co-author DOI 10.1158/1535-7163.mct-21-0474↗
  21. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. Co-author DOI 10.1186/s12885-022-10449-y↗
  22. The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine. Last author DOI 10.1186/s40168-022-01262-7↗
  23. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. Last author DOI 10.1200/jco.21.02492↗
  24. Application of modified gemcitabine-loaded solid lipid nanoparticle in the treatment of pancreatic cancer patient-derived xenograft model Co-author DOI 10.21203/rs.3.rs-1777458/v1↗
  25. From bench to bedside: Pursuing equity in precision medicine approaches to pancreatic cancer care. Co-author DOI 10.3389/fonc.2022.1086779↗
  26. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.806963↗
  27. Patient-Derived Pancreatic Cancer Cells Induce C2C12 Myotube Atrophy by Releasing Hsp70 and Hsp90. First author DOI 10.3390/cells11172756↗
  28. Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1002/onco.13853↗
  29. Diversity and Inclusion in Pancreatic Cancer Clinical Trials. Last author DOI 10.1053/j.gastro.2021.06.079↗
  30. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-20-1422↗
  31. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4781↗
  32. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Co-author DOI 10.3389/fonc.2021.688377↗
  33. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Co-author DOI 10.3390/cancers13030440↗
  34. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Last author DOI 10.3390/cancers13040809↗
  35. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. Last author DOI 10.1002/cam4.3042↗
  36. Protein Signatures and Tissue Diagnosis of Pancreatic Cancer. Co-author DOI 10.1016/j.jamcollsurg.2019.10.002↗
  37. Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells. Co-author DOI 10.1016/j.jddst.2019.101374↗
  38. Comparative study on contrast enhancement of Magnevist and Magnevist-loaded nanoparticles in pancreatic cancer PDX model monitored by MRI. Co-author DOI 10.1186/s12645-020-00061-9↗
  39. Nicotine Induces IL-8 Secretion from Pancreatic Cancer Stroma and Worsens Cancer-Induced Cachexia. Last author DOI 10.3390/cancers12020329↗
  40. Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) mode… Co-author DOI 10.1007/s10637-018-0647-0↗
  41. A deeper understanding of the tumor microenvironment in pancreatic cancer: the key to developing effective immunotherapies. First author DOI 10.21037/atm.2019.03.14↗
  42. IL-8 Released from Human Pancreatic Cancer and Tumor-Associated Stromal Cells Signals through a CXCR2-ERK1/2 Axis to Induce Muscle Atrophy. Co-author DOI 10.3390/cancers11121863↗
  43. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. Co-author DOI 10.1007/s12029-017-0021-z↗
  44. Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabiliz… Co-author DOI 10.1093/carcin/bgy114↗
  45. Skeletal Muscle Fibrosis in Pancreatic Cancer Patients with Respect to Survival. Co-author DOI 10.1093/jncics/pky043↗
  46. Pancreatic Cancer Related Health Disparities: A Commentary. Co-author DOI 10.3390/cancers10070235↗
  47. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. Last author DOI 10.3390/ijms19123836↗
  48. A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Last author DOI 10.1016/j.surg.2016.09.038↗
  49. Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Huma… Last author DOI 10.1097/mpa.0000000000000843↗
  50. Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1765↗

Grants 4

  1. Community Outreach Core U54CA233444↗
  2. United for Health Excellence - Living PDX Program (U4HELPP) U54CA283762↗
  3. Precision medicine for pancreatic cancer. Biomarker-guided drug delivery of platinum to tumors R41CA287830↗
  4. Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer R01CA242003↗

Closest collaborators

The 25 strongest of 160 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steven J. Hughes · 22 shared papers, 2015–2026 · strength 2.51
  2. Patrick W. Underwood · 17 shared papers, 2018–2024 · strength 2.43
  3. Andrea N. Riner · 12 shared papers, 2020–2026 · strength 2.15
  4. Kelly M. Herremans · 11 shared papers, 2020–2026 · strength 2.00
  5. Thomas J. George · 17 shared papers, 2014–2025 · strength 1.62
  6. Andrew R. Judge · 13 shared papers, 2017–2025 · strength 1.62
  7. Sarah M. Judge · 12 shared papers, 2017–2025 · strength 1.50
  8. Vignesh Vudatha · 7 shared papers, 2022–2024 · strength 1.16
  9. Daohong Zhou · 3 shared papers, 1 shared grant, 2022–2025 · strength 1.10
  10. Song Han · 8 shared papers, 2015–2025 · strength 1.01
  11. Joshua (Chuck) Harrell · 1 shared grant, 2026 · strength 1.00
  12. Nicholas Taylor Woods · 1 shared grant, 2026 · strength 1.00
  13. Guangrong Zheng · 2 shared papers, 1 shared grant, 2022–2025 · strength 0.97
  14. Daniel Delitto · 14 shared papers, 2015–2020 · strength 0.96
  15. Nicholas Patrick Farrell · 1 shared grant, 2024 · strength 0.91
  16. Michael H. Gerber · 9 shared papers, 2017–2023 · strength 0.83
  17. Edward Agyare · 6 shared papers, 2018–2023 · strength 0.81
  18. Miles E. Cameron · 6 shared papers, 2018–2022 · strength 0.75
  19. Ibrahim Nassour · 3 shared papers, 2022–2026 · strength 0.64
  20. Jennifer B. Permuth · 6 shared papers, 2016–2025 · strength 0.64
  21. Bo Han · 4 shared papers, 2020–2023 · strength 0.61
  22. Mokenge Peter Malafa · 5 shared papers, 2016–2025 · strength 0.58
  23. Daniel R. Principe · 4 shared papers, 2021–2022 · strength 0.58
  24. Hidayatullah G. Munshi · 4 shared papers, 2021–2022 · strength 0.58
  25. Jason B. Fleming · 4 shared papers, 2021–2025 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.